Heritable human gene editing in global context: national and international policy challenges by Rosemann, Achim et al.
Heritable human gene editing in global context: national and 
international policy challenges
Article  (Published Version)
http://sro.sussex.ac.uk
Rosemann, Achim, Balen, Adam, Nerlich, Brigitte, Hauskeller, Christine, Sleeboom-Faulkner, 
Margaret, Hartley, Sarah, Zhang, Xinqing and Lee, Nick (2019) Heritable human gene editing in 
global context: national and international policy challenges. Hastings Center Report, 49 (3). pp. 
30-41. ISSN 1552-146X 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/84560/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
30   HASTINGS CENTER REPORT May-June 2019
In July 2018, the Nuffield Council on Bioethics in the United Kingdom published a report that con-cluded that the “use of heritable genome editing 
to influence the characteristics of future generations 
could be ethically acceptable in some circumstances,” 
as long as specific preconditions are met.1 The report 
followed a 2017 U.S. National Academies of the Sci-
ences, Engineering, and Medicine (NASEM) publi-
cation that recommended permitting clinical trials 
for the prevention of severe monogenetic disorders, 
as long as these are conducted within a robust and 
effective regulatory framework.2 These reports and a 
range of other publications3 have also demanded that 
clinical research and applications should be preceded 
and accompanied by “extensive and inclusive pub-
lic participation,”4 so as to collectively consider the 
possible uses, limits, and risks of gene editing tech-
nologies. A central concern of many of these studies 
has been to anticipate and reflect on the short- and 
long-term societal implications of heritable genome 
editing, not only for people who are born as a result 
of genome editing, but also for current and future 
societies at large. Ethical issues raised in the publi-
cations include, among others, the significance of 
solidarity, social justice, and responsible innovation 
to prevent adverse medical effects, discrimination, 
disadvantages, and societal divisions.5 
Then, on November 25, 2018, just days before 
the start of the Second International Summit on Hu-
man Genome Editing, in Hong Kong, news broke 
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that a woman had given birth to two 
babies whose genomes had been edit-
ed by a research team in China.6 This 
use of genome editing was widely 
condemned as irresponsible and as 
failing to conform with internation-
al norms.7 It also had a significant 
impact on regulatory debates. The 
organizing committee of the Hong 
Kong summit declared, for example, 
the need for “a rigorous, responsible 
translational pathway toward” “clini-
cal trials of germline editing” that 
establishes international “standards 
for preclinical evidence and accuracy 
of gene modification, assessment of 
competency for practitioners of clini-
cal trials, [and] enforceable standards 
of professional behavior.”8 This state-
ment was criticized, however, by both 
scientists and social scientists because 
it deemphasized the commitment to 
a “broad societal consensus” that was 
evident in the NASEM and Nuffield 
Council reports and in other publica-
tions.9 A group of scientists and ethi-
cists working with the geneticist Eric 
Lander, for instance, now demanded 
the adoption of a temporary global 
moratorium on all clinical uses of hu-
man germline editing, arguing that 
the decision to move toward clinical 
applications should not be made by 
the scientific or medical community, 
but by societies as a whole.10 At the 
same time, the World Health Orga-
nization responded to the news of the 
genetically modified babies in China 
by setting up a new advisory com-
mittee to develop global standards 
for the governance and oversight of 
human genome editing, aiming to 
work toward a strong international 
governance framework.11 In a first 
step, this panel suggested the creation 
of a global registry of all human gene 
editing research, which would allow 
oversight and transparent access to 
the details of current and future stud-
ies by interested parties.12 
A central problem for the interna-
tional governance of germline gene 
editing is that there are important 
differences in attitudes and values as 
well as ethical and health care consid-
erations around the world. These dif-
ferences are reflected in a complicated 
and diverse regulatory landscape. 
Several publications have sought to 
develop a broad, comparative un-
derstanding of existing regulatory 
conditions in different countries13 
and to sample international legal 
and regulatory frameworks that may 
influence the governance of clini-
cal applications in this field.14 Other 
articles have explored the social and 
ethical dimensions of this technology 
in relation to a variety of topics, such 
as the interests and rights of people 
with disabilities;15 reproductive au-
tonomy;16 the history of eugenics 
and racism;17 the gendered, ethnic, 
and socioeconomic dimensions of ge-
nome editing;18 the consequences of 
gene editing for future generations;19 
and challenges related to informed 
consent.20 Other work has compared 
existing regulatory frameworks for 
basic and preclinical research as well 
as potential reproductive applications 
of human genome editing.21 A central 
point of discussion in these studies 
was whether reproductive uses would 
be legally permissible in individual 
countries and whether clinical appli-
cations could emerge in the context 
of regulatory gaps and gray areas.22
However, a systematic investiga-
tion of the possible effects of inter-
national regulatory differences, and 
of the challenges likely to arise for 
national governments once clini-
cal applications in this field become 
available at a global scale, has not yet 
been conducted. Neither the recent 
Nuffield Council report, nor the 
NASEM report, nor other previous 
studies have systematically addressed 
this issue. This is an important 
shortcoming. The incident in China 
suggests that different forms of regu-
latory oversight as well as differences 
in social environments, clinical cul-
tures, and patient needs will probably 
result in additional premature and ir-
responsible applications of heritable 
genome editing, which could expose 
prospective parents and their em-
bryos, fetuses, and of course, children 
and their descendants to substantial 
risks.
Systematic comparative stud-
ies that explore issues related to the 
governance of this technology from 
different national and international 
perspectives are needed to address 
the lack of knowledge in this area. 
In this research report, we contrib-
ute to filling this gap by presenting 
views of stakeholders in the United 
Kingdom on challenges to the gov-
ernance of heritable genome editing. 
We present findings from a multi-
stakeholder study conducted in the 
United Kingdom between October 
2016 and January 2018 and funded 
by the Wellcome Trust. This research 
included interviews, literature analy-
sis, and a workshop. We involved 
leading U.K. scientists, in vitro fer-
tilization (IVF) clinicians, and rep-
resentatives from regulatory bodies, 
patient organizations, and other civil 
societal organizations, as well as fertil-
ity companies.
Part one of this article explores 
stakeholder perceptions of possible 
global developments in heritable ge-
nome editing and associated risks and 
governance challenges with respect to 
two overarching themes. The first 
theme is issues related to the situation 
and well-being of fertility patients 
International differences in attitudes and values as 
well as ethical and health care considerations make 
for a complicated and diverse regulatory landscape.
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and babies whose genomes are ed-
ited. In considering these issues, we 
focus on the potential challenges of 
germline gene therapy tourism and 
the emergence of commercial clinics 
that are likely to offer potential pa-
tients germline editing of embryos 
for nontherapeutic purposes. Illegal 
and rogue clinics will operate outside 
of systematic clinical research proto-
cols and oversight, prior to reliable 
clinical studies for the interventions 
they offer.23 Yet, as in other fields of 
medicine, some commercial clinics 
may claim to provide clinical applica-
tions as part of a research framework. 
Many clinics offer treatments in a 
“gray zone” between the two poles of 
“rigorous science” and “quackery.”24 
This can make it difficult to draw a 
clear line between rogue clinical ap-
plications and legitimate clinical 
research.
The second theme is issues for 
researchers, fertility clinics, and cor-
porations that aim to develop, apply, 
and commercialize this technology in 
the context of international research 
or commercial partnerships. These 
partnerships can be built around the 
coorganization of clinical research 
studies, or they can target the provi-
sion of unproven, or nonsystemati-
cally evidenced, clinical interventions 
on a commercial basis in permissive 
locations. 
In the second part of the article, 
we present a range of policy options 
that were generated during the work-
shop in relation to the challenges dis-
cussed in part one. While the options 
represent the views of stakeholders 
in the United Kingdom, they ad-
dress issues and possible clinical (and 
commercial) developments of inter-
national relevance. The surfacing of 
premature, irresponsible, or rogue 
applications; the potential emergence 
of transnational germline therapy 
tourism; and the possibility of genetic 
enhancement are shared, global chal-
lenges. For this reason, the policy op-
tions put forward in this report have 
the potential to contribute to inter-
national dialogue and inform the de-
velopment of collective responses to 
METHODOLOGY
We designed our investigation of stakeholders’ views of the challenges and options for the governance of heritable ge-
nome editing with the methodological approach known as for-
ward engagement, which aims to identify challenges that arise 
from new technologies as well as possibilities for adaptation 
and governance as far in advance as possible.1 Our aim was 
to initiate a systematic thought process among multiple stake-
holders in the United Kingdom about long-range issues in the 
governance of human genome editing and to help inform col-
lective responses and policy responses at an early stage.2 To 
achieve this aim, we have combined multistakeholder delibera-
tion, semistandardized interviews, video interviews, and docu-
mentary research. 
The project consisted of two phases. Phase one involved eigh-
teen semistandardized in-depth interviews with U.K. stakehold-
ers with varied professional backgrounds (as described in this 
article’s introduction) as well as documentary research (policy 
reports, public commentary, and relevant academic publica-
tions). 
Phase two consisted of the organization of a one-day multi-
stakeholder workshop that was held in June 2017 in London. 
The workshop methodology involved focus group discussions, 
plenary discussions, and short video interviews. Hypothetical 
case scenarios were used as a focus device to stimulate discus-
sions of likely challenges and reflection on possible responses. 
The case studies were based on the phase-one interviews and 
complementary insights from newspaper and media coverage. 
Three potential scenarios that are likely to occur in the next 
ten to thirty years were discussed: clinicians from countries in 
which heritable gene editing is prohibited collaborate with IVF 
clinics in more leniently regulated countries to achieve first-in-
human applications in a legal gray area, transnational germline 
gene therapy tourism emerges, and commerce-driven (and pos-
sibly fraudulent) applications of “genetic enhancement” surface. 
Parallel to the workshop, six 10- to 15-minute video interviews 
were conducted. All data presented in this article have been an-
onymized to protect the interests of project participants and the 
organizations they represent. 
The stakeholder-participants in this research were based in 
the United Kingdom, and our findings have been shaped by 
their perspectives. Stakeholders from other countries may ex-
press other views or have different priorities. However, all the 
possible clinical developments discussed in this report concern 
global challenges and risks that are likely to affect humanity in 
general. The ideas and options presented here thus contribute 
to the ongoing international dialogue and inform academic and 
policy debates on heritable genome editing at national and in-
ternational levels. 
1. L. S. Fuerth and E. M. Faber, Anticipatory Governance: Practical Upgrades 
(Washington, DC: National Defense University Press, 2012), http://www.dtic.mil/
dtic/tr/fulltext/u2/a585519.pdf.
2. Ibid.
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heritable genome editing. Before get-
ting to these empirical findings, we 
briefly discuss possible applications of 
heritable genome editing technology 
and provide a more detailed overview 
of the study’s methodology. 
Heritable Genome Editing: 
From Research to Applications 
The bioethicist and policy analyst Tetsuya Ishii has noted three 
objectives for which heritable gene 
editing is expected to be used: the 
prevention of monogenic conditions 
(such as Huntington disease, Tay-
Sachs disease, and cystic fibrosis), the 
maximization of reproductive choices 
during in vitro fertilization (such as 
the prevention of baldness and the 
choice of eye, hair, and skin color), 
and genetic enhancement (for ex-
ample, for height, muscularity, and 
learning and memory—although 
these are not all attributable solely 
to genetics).25 Current recommenda-
tions to permit clinical trials with ge-
netically modified gametes, zygotes, 
or embryos relate exclusively to the 
prevention of severe genetic disor-
ders. However, as Ishii has pointed 
out, while certain increased reproduc-
tive choices and genetic enhancement 
are seen by many as problematic, in 
a diverse regulatory environment, the 
emergence of these applications in ar-
tificial reproductive technology cen-
ters seem likely in the mid- to long 
term.26
Others have made similar assess-
ments. The NASEM Committee on 
Human Genome Editing warned, 
for instance, that “regulatory ha-
vens” could emerge that would tempt 
providers or consumers to travel to 
jurisdictions with more lenient or 
nonexistent regulations to undergo 
procedures that are prohibited in oth-
er countries.27 Developments in the 
field of regenerative medicine have 
shown, for instance, that in many 
countries, for-profit applications 
emerge long before reliable regula-
tory controls are in place, often in a 
legal gray area and with problematic 
consequences.28 Considering the po-
tential implications of heritable gene 
editing for human societies and the 
fact that germline engineering will be 
difficult to control at a global level,29 
an exploration of possible develop-
ments, challenges, and risks in this 
field is important. 
A more general problem with the 
clinical translation of heritable ge-
nome editing technology is that it is 
difficult to draw a clear line between 
clinical applications and clinical re-
search. Some clinics, as we have stated 
above, may offer clinical applications 
of heritable genome editing on a 
commercial basis outside of rigorous 
(internationally accepted) research 
protocols and oversight, but they still 
may be involved in preclinical re-
search or may implement follow-up 
procedures that monitor the genetic 
or functional effects of the interven-
tion during pregnancy, after birth, or 
during childhood and adulthood. 
Another problem is that the es-
tablished clinical translation path-
way for new therapies—namely, 
multistage controlled trial system to 
determine the safety and efficacy of 
a tested treatment—is not available 
for heritable genome editing. Germ-
line therapy cannot be part of a con-
trolled study design because there are 
no controls (except other “unmodi-
fied” individual embryos and human 
beings) for comparison. In addition, 
exploratory (phase zero or phase one) 
trials that use only very small doses 
of a new drug in a small number of 
patients to establish its safety cannot 
be conducted for germline therapy. 
In standard first-in-human trials, an 
administered drug can be withdrawn 
instantaneously after the emergence 
of adverse effects, and, if necessary, 
treatments can be provided to coun-
ter adverse effects. For germline gene 
therapy, these options do not exist. 
Once a genetically modified embryo 
has been implanted into the uterus, 
the intervention cannot be reversed. 
If prenatal diagnosis reveals a defect 
caused by the gene therapy that will 
seriously affect fetal development 
and the future life of a person after 
birth, the primary options to prevent 
the negative effects of the treatment 
are through abortion or, where le-
gal, postnatal euthanasia. If the fetus 
develops into a baby who survives, 
the person will have to live with the 
consequences of the intervention for 
the rest of her or his life and might 
transmit the effects to subsequent 
generations. In consequence, every 
reproductive intervention, even a 
first-in-human application that is 
part of a systematic research protocol, 
is an immediate full clinical applica-
tion whose effects cannot be reversed. 
These considerations do not rule 
out the possibility of making and 
maintaining a clear distinction be-
tween systematic fully monitored 
and recorded research-based appli-
cations and other—ethically more 
problematic—forms of experimental 
for-profit applications. Nevertheless, 
the fuzzy boundaries between clini-
cal research and clinical applications 
will have important regulatory im-
plications if and when a translational 
The fuzzy boundaries between clinical research and 
clinical applications will have important regulatory 
implications if and when a translational pathway and 
oversight for heritable genome editing are developed.
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pathway and oversight for heritable 
genome editing are developed. 
Challenges for Fertility Patients 
and Babies
During the first phase of the project, two central themes 
emerged that were examined further 
in the context of the multistakehold-
er workshop: the rise of reproductive 
tourism and the expansion of rogue 
IVF clinics that offer gene editing for 
nontherapeutic purposes.30 
Germline therapy tourism. Repro-
ductive tourism is a form of medical 
tourism in which fertility patients 
travel to other countries to “receive a 
specific treatment or to exercise per-
sonal reproductive choice.”31 These 
reproductive travels are frequently 
based on the legal prohibition in 
some countries of specific technolo-
gies that, in some other countries, are 
legal or are tolerated in a gray zone. 
The legal analyst Glenn Cohen has 
called these forms of medical travel 
“circumvention tourism” because 
they circumvent domestic prohibi-
tions on accessing specific medical 
services.32 Surrogacy is a good exam-
ple. As the South African sociologist 
Amrita Pande has shown, fertility pa-
tients from high-income countries in 
which surrogacy is banned travel to 
India and other societies where sur-
rogacy is permitted and surrogacy 
mothers can be hired for a low pay-
ment.33 Many of our research partici-
pants expected that circumvention 
tourism could also occur with heri-
table gene editing, at least as long as 
these treatments are not accessible in 
the United Kingdom. Participants as-
sumed that IVF clinics in countries 
without regulatory frameworks or 
with permissive or flexibly enforced 
ones were likely to provide germline 
gene therapy for monogenic disorders 
much earlier than clinics in coun-
tries with more restrictive regulatory 
controls. Many participants saw this 
situation as both a threat to the well-
being of parents and children and a 
challenge to the future development 
of this field.
While most participants said they 
understood the motivation of pro-
spective parents to seek germline gene 
therapy for children who would oth-
erwise suffer from severe genetic dis-
orders, they also expressed a range of 
concerns, some of which were sum-
marized by a senior IVF clinician in 
our workshop:
Parents, [have] the desire to seek 
the best for their future children. 
So we understand why, if the 
treatment was not permissible in 
the U.K., parents may wish to go 
overseas. However, we felt strongly 
that any such treatment needs to 
be part of a continuum of appro-
priate preclinical and then clini-
cal studies, transparent and open 
with proper ethical review and 
follow-up. And, of course, we were 
concerned about . . . a child be-
ing born [and coming] back to the 
U.K., needing to be looked after 
and followed-up by the NHS [Na-
tional Health Service], and the po-
tential implications [of this]. 
The main concern here is that, in 
some countries that lack or have le-
nient regulatory conditions, early-
stage reproductive applications could, 
and likely will, be provided outside of 
a systematic research framework and 
also independent of the review and 
approval mechanisms of regulatory 
agencies. Most interviewees stated 
that this would be problematic for 
the responsible development of heri-
table genome editing technology as a 
whole because it would prevent the 
generation and publication of reliable 
data, including of negative results. 
One issue highlighted in inter-
views and workshop discussions 
was that the early-stage provision of 
germline therapies in some clinics 
was likely to be driven primarily by 
financial motives or professional van-
ity, instead of a strong clinical justi-
fication and reliable preclinical data. 
As several interviewees mentioned, 
in a global environment where the 
generation of profits is often more 
important than scientific integrity, 
clinical applications may be offered 
prematurely and irresponsibly. As a 
result, fertility patients, their embry-
os, children, and subsequent genera-
tions could be exposed to significant 
unjustified psychological and health 
risks. Potential adverse effects or 
problems, such as increased miscar-
riage rates, are likely to be kept secret 
and not to be shared with the scientif-
ic community. The criteria on which 
institutional or ethics review boards 
have based their assessments and ap-
provals of reproductive applications 
are also likely to remain unclear.
Participants also expressed concern 
about the risks of missing long-term 
follow-up monitoring in overseas IVF 
clinics, especially if patients travel to 
these clinics from abroad. To estab-
lish a reliable evidence base, the U.S. 
National Academies of the Sciences, 
Engineering, and Medicine34 and 
other researchers35 have recommend-
ed long-term, possibly multigenera-
tional, follow-up of individuals who 
have received heritable gene editing. 
Still other concerns relate to le-
gal responsibilities: Who is liable for 
reproductive applications in other 
countries if something goes wrong? 
Can patients take legal action against 
an overseas clinic if their child suffers 
from (potentially irreversible) adverse 
effects? Will the NHS be ready to pay 
for subsequent treatments and care 
arrangements? As research on other 
areas of medical tourism has shown, 
medical tourists paying out of pocket 
often face the problem of legal liabil-
ity. Patients face a lower likelihood 
and degree of recovery for adverse ef-
fects or injuries sustained as a result 
of medical tourism.36 Moreover, such 
adverse effects may require follow-up 
treatment in patients’ home coun-
tries, which can cause additional costs 
for national health systems. 
“Rogue” IVF clinics and germline 
therapy for nontherapeutic purposes. 
Reproductive tourism sometimes in-
volves the use of rogue clinics. People 
travel, for example, to China to use 
clinics offering surrogacy and sex 
selection, practices that were out-
lawed there in 2001. Despite the 
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government’s repeated efforts to close 
down this market and despite the risk 
of punishment, clinics using artificial 
reproductive technology (ART) have 
been incentivized by a steady demand 
for these services.37 Illegal or gray-ar-
ea applications in stem cell medicine 
are another example. As reported by 
Dominique McMahon,38 a global in-
dustry of rogue stem cell clinics has 
emerged since the mid-2000s. Hun-
dreds of clinics in numerous coun-
tries, including the United States and 
other high-income countries, offer 
unauthorized stem cell interventions 
whose safety and effectiveness have 
not been systemically proven.39
Many of our interviewees expressed 
concern that similar developments 
might occur in regard to heritable 
gene editing. The surfacing of rogue 
clinics was seen as particularly likely 
in countries with no regulation or 
lenient regulatory infrastructures. A 
senior researcher stated that excite-
ment about heritable genome edit-
ing could lead to hype and fuel the 
provision of heritable genome editing 
in illegal or gray-area ART clinics. He 
and other respondents considered it 
very likely that unscrupulous, mis-
guided, or inexperienced clinicians 
will offer germline therapy to patients 
who desire a child without a genetic 
disease. Similar concerns have also 
been expressed by the bioethicist and 
legal scholar Alta Charo, who also has 
warned of the emergence of germline 
therapy tourism.40 According to Cha-
ro, medical and reproductive tourism 
is not necessarily a bad thing, but it 
should take place only after the de-
velopment of safe and effective inter-
ventions and should not precede or 
be a part of the clinical research and 
development process. 
Interviewees expected that these 
clinics would initially focus solely on 
the correction of monogenic medical 
conditions, but that, over time, once 
germline therapy for single gene dis-
orders was more widely available and 
accepted, clinics would also provide 
treatments for polygenic conditions 
and nontherapeutic purposes, includ-
ing forms of genetic enhancement. 
CRISPR coinventor Jennifer Doudna 
conveyed similar worries during her 
2017 visit at the Royal Society: “I 
certainly hear about work . . . that is 
aimed at helping in vitro fertilization 
clinics to apply [germline gene edit-
ing] for correcting genetic diseases, 
or for making other kinds of genetic 
changes. And also to commercial-
ize that. And that is . . . where I feel 
more uncomfortable. I certainly feel 
more uncomfortable with a company 
trying to make money, telling people 
. . . . “Hey, you can have a better child 
. . . when you do this . . .”41
Project participants defined 
“rogue” IVF clinics in various ways. 
The most important criteria used to 
differentiate these clinics from pro-
viders of more “legitimate” clinical 
services were that they were likely to:
• provide insufficient information 
about the kinds of methods and 
protocols they use;
• work with false claims and mis-
leading advertisement strategies;
• provide clinical services that are 
based on insufficient forms of pre-
clinical or clinical evidence;
• offer nontherapeutic or enhance-
ment applications in a legal gray 
area or even in the context of legal 
prohibition;
• sell potential “snake oil” inter-
ventions, which would not involve 
gene editing at all despite being 
sold and advertised as such inter-
ventions; and
• expose IVF patients and their 
offspring to uncertain and unjus-
tifiable risks. 
Participants identified four key 
policy challenges related to illegal or 
rogue IVF clinics offering heritable 
gene editing to patients. The first is to 
make sure that germline gene editing 
is provided only in a well-regulated, 
controlled environment. This would 
include preventing clinical entrepre-
neurs from trying to exploit the de-
sire of prospective parents to have a 
healthy baby with specific physical, 
mental, or cognitive characteristics, 
at least as long as the clinical utility 
of these interventions was not reliably 
established and a public consensus on 
the desirability of these applications 
was not yet achieved. 
A second challenge is to protect 
patients from deceptive marketing 
and advertising, including that with-
out sufficient information about pos-
sible adverse effects and risks. Public 
education of risk groups and caregiv-
ers was seen as a means to achieve this 
goal, to inform people of the most 
recent stage in the technique’s devel-
opments, about potential individual 
and societal consequences, and about 
possible adverse effects and risks. 
Such education could be developed 
and offered by patient organizations, 
health service providers, and regula-
tory bodies.
Numerous interviewees expected that clinical  
applications aimed at genetic enhancement will be 
offered, with the risk of adverse effects considerably 
higher than for the treatment of monogenic disorders.
36   HASTINGS CENTER REPORT May-June 2019
Participants saw the emergence 
of enhancement-oriented forms of 
germline therapy as another chal-
lenge. Numerous interviewees ex-
pected that, in the mid- to long 
term, clinical applications intended 
to achieve some form of genetic en-
hancement would be offered to pa-
tients. Because these interventions 
would inevitably involve the modifi-
cation of large numbers of gene loca-
tions, the risk of adverse effects was 
expected to be considerably higher 
than for the treatment of monogenic 
disorders. Most respondents argued 
in favor of a prohibition against en-
hancement applications but recog-
nized that, at a global level, such a 
ban would be difficult to achieve.
Finally, participants identified the 
need to avoid the provision of fraud-
ulent interventions, that is, clinical 
applications that claim to involve 
germline therapy when in fact they 
do not. The likelihood of such de-
ceitful interventions was seen to be 
particularly high with regard to non-
therapeutic or “enhancement” appli-
cations—because the actual efficacy 
and effects of these “treatments” will 
be extremely difficult to verify. Inter-
viewees pointed out the following: 
• “In principle—as happened 
with for-profit stem cell interven-
tions—clinics or corporations 
can work with entirely fraudulent 
claims” (IVF Clinician 1).
• “One would never know how 
well it would have worked” (Se-
nior Researcher). 
• “There will be a lack of evidence 
for these interventions, but private 
clinics and corporations are likely 
to do it nonetheless” (IVF Clini-
cian 2).
These concerns closely echo Ishii’s 
estimation that nontherapeutic and 
enhancement applications are prob-
ably inevitable at a global level and 
are only a matter of time.42 They 
also resonate with Harald König’s as-
sessment that there is an “illusion of 
control” in many of the current poli-
cy debates on germline engineering.43 
He has pointed out that a central as-
sumption in current discussions on 
the governance of heritable genome 
editing is the notion that “technolo-
gies can be prohibited . . . until they 
are ‘safe enough’—and, moreover, 
that this can be done globally.”44 Ac-
cording to König, it is an illusion 
that such a universal level of control 
can be achieved, partly because cur-
rent regulations for germline genome 
editing vary considerably across the 
globe, partly because there are differ-
ent ethical and moral ideas on human 
genome editing, and partly because 
of the economic incentives that drive 
innovation processes in this field.45
Challenges Related to 
Researchers, Fertility Clinics, 
and Corporations
A second set of policy challenges that the project examined re-
lated to the situation and activities 
of researchers, fertility clinics, and 
corporations that are likely to de-
velop, apply, and commercialize this 
technology over the course of the 
next years and decades. Throughout 
the interviews and workshop, our 
aim was to identify obstacles to the 
realization of responsible forms of 
transnational research and corporate 
practices in an environment that is 
characterized by significant differ-
ences in research cultures, regulatory 
structures, and business and commer-
cialization practices. 
U.K. researchers and corporations 
operating abroad to avoid regulatory 
restrictions. A widespread concern 
among participants was that U.K. 
researchers, clinicians, and fertility 
companies would seek opportunities 
to provide and commercialize heri-
table genome editing applications in 
more permissive countries, especially 
as long as the technology was not per-
mitted in the United Kingdom. An 
example that came up repeatedly in 
interviews and group discussions was 
the first application of mitochondrial 
gene transfer in Mexico in 2015, a 
case in which U.S. clinicians traveled 
to Mexico to create a “three-parent” 
embryo that then developed into a 
healthy baby, despite the fact that the 
technology was not approved in the 
United States.46 Participants expected 
that a similar development could oc-
cur with regard to heritable genome 
editing. In open discussions during 
the workshop, there was unanimous 
consensus that if these clinical ap-
plications were not part of system-
atic and formally approved clinical 
studies, this was bad practice that 
should be addressed and prevented 
by U.K. government bodies, research 
councils, and scientific and medical 
organizations. 
In interviews, a widely expressed 
concern was that the operation of 
U.K. researchers and corporations in 
more permissively regulated coun-
tries could harm the scientific status 
of the United Kingdom and prevent 
progress for the clinical validation of 
heritable genome editing through a 
focus on profit opportunities rather 
than robust data. However, some 
interviewees supported the idea that 
U.K. researchers and fertility compa-
nies could provide heritable genome 
editing treatments in more leniently 
regulated countries if these collabora-
tions would enable U.K. patients to 
access potentially beneficial interven-
tions for severe genetic disorders that 
are not yet available in the United 
Kingdom. This view was particularly 
notable among representatives of pa-
tient organizations. These spokesper-
sons argued that preventing patients 
from seeking potentially beneficial 
treatments abroad was a violation of 
patients’ rights and ignored patients’ 
suffering. One of the representatives 
stated that acknowledging reproduc-
tive freedom and parental autonomy 
is especially important in the con-
text of the burden and inevitabil-
ity of serious genetic diseases and of 
the instinctive and intuitive desire of 
parents to have an unaffected child. 
The spokesperson of another patient 
organization stressed that the knowl-
edge that a potential treatment was 
available, albeit in a different country 
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with less rigorous regulations, instills 
a psychological motivation to use 
this treatment. That is why, from his 
view, inaction by the U.K. govern-
ment to permit heritable genome ed-
iting for monogenic disorders would 
ultimately encourage patients to 
travel to other countries. 
Involvement of U.K. researchers 
in overseas heritable genome edit-
ing research trials. Another form of 
transnational interaction discussed 
during the project was the involve-
ment of U.K. researchers in overseas 
clinical research studies that would 
involve heritable genome editing. 
While interviewees thought that, at 
present, any form of clinical research 
in this field was premature, there was 
a consensus that once the technology 
was proven to be safer and more re-
liable, participation in international 
clinical studies would be acceptable. 
There was also a widespread agree-
ment that such interventions must 
be provided as part of a systematic, 
science-driven clinical study format 
and that these studies should be 
formally approved by a government 
agency and conducted in line with 
international guidelines. As a set of 
minimum criteria, participants sug-
gested the following benchmarks: 
treatment protocols are transparent, 
independent ethical review occurs, 
approval comes from a national-
level government agency, clinical 
applications are based on sufficient 
preclinical evidence on safety and 
efficacy, such applications follow 
from a convincing medical rationale 
that justifies the interventions, and 
clinical interventions are conducted 
in the context of an international 
dialogue and under systematic, in-
dependent peer review. Participants 
judged that, if these conditions were 
met, involvement of U.K. researchers 
in overseas heritable genome editing 
trials would be acceptable even if 
such trials were still prohibited in the 
United Kingdom.
Policy Options
How should policy-makers, pro-fessional bodies, and other 
stakeholders respond to the challeng-
es we describe in this article to maxi-
mize patient safety and to enable 
responsible forms of clinical trans-
lation and ethically robust forms of 
international research and corporate 
collaborations? In the context of 
interviews and the workshop, proj-
ect participants developed six broad 
policy options. 
Proactive regulation. The major-
ity of participants argued in favor of 
proactive legislation that would en-
able clinical heritable genome edit-
ing research under carefully defined 
conditions. As the director of an IVF 
unit put it, the creation of a permis-
sive but carefully regulated research 
environment for heritable genome 
editing in the United Kingdom 
would prevent reproductive tour-
ism and allow initial clinical appli-
cations under a systematic research 
framework: 
If [this technology] is found to 
be safe, and only if it is found to 
be safe, [we must] ensure that we 
have tight, permissive regulation 
enabling those parents who may 
want to go through these thera-
pies for their future children to 
have the ability to have safe thera-
pies in the U.K., rather than feel-
ing the need to go overseas and to 
be potentially treated by rogue cli-
nicians, rogue scientists, in rogue 
clinics, where we won’t necessarily 
have insight into the failures, the 
mistakes, the problems that may 
occur. (Interviewee 14)
Several participants emphasized 
that the United Kingdom has a com-
prehensive and mature regulatory 
framework that governs ARTs, em-
bryo research, and the creation and 
use of human embryos for research 
purposes and that this framework 
can, in principle, be extended to reg-
ulate first-in-human applications of 
heritable gene editing. While there 
was a shared understanding that it 
was now too early to change legis-
lation and permit clinical applica-
tions, various participants thought 
it was crucial that the U.K. govern-
ment start to anticipate and address 
some of the key concerns of heritable 
genome editing technology and to 
begin developing appropriate policy 
responses. A senior researcher, for 
instance, mentioned that the U.K. 
government needs to “think about 
what forms regulation would take 
to govern this area of potential clini-
cal practice.” He also stated that “it 
is quite clear that we are not ready 
yet. There are still lots of issues that 
need to be sorted out. But it is im-
portant to have government . . . start 
thinking about this now, as an issue” 
(Interviewee 12). This view is also re-
flected in the statement of a senior 
IVF clinician: “This technology field 
is developing extremely quickly, and 
so we need to take stock of things, 
that it is properly regulated and that 
we have appropriately published pre-
clinical studies before we bring this 
technology into clinical practice” 
(Interviewee 21).
While project participants did 
not have an answer to the question 
of when first-in-human applications 
should be allowed, they acknowl-
edged that there is a fundamental 
A widespread concern was that U.K. researchers,  
clinicians, and fertility companies would seek  
opportunities in more permissive countries.
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tension between the development of 
a slow and careful regulatory frame-
work in the United Kingdom and 
the pressures U.K. science is likely 
to experience from developments in 
other parts of the world. As the same 
senior IVF clinician put it, 
At the moment, I think it is essen-
tial . . . that we move cautiously, 
that we move slowly, but at the 
same time, we have to recognize 
that there are scientists out there 
in the world who may be mov-
ing faster than we would like, and 
that brings the danger of people 
going overseas for treatments that 
are not regulated in the U.K. So 
if we accept that these sorts of 
therapies are going to come into 
clinical practice, we need to en-
sure that our regulation occurs in 
a timely manner. (Interviewee 21)
Broad public engagement. 
A closely related policy option 
that project participants repeatedly 
emphasized was the initiation of far-
reaching public engagement exer-
cises. A widespread view was that the 
United Kingdom is currently lacking 
in public and policy debates on re-
productive gene editing and on the 
potential uses of heritable genome 
editing. Broad public engagement 
was seen as a central requirement to 
ensure that regulatory options and 
policies would correspond to the 
needs and perceptions of patients, 
laypeople, and society at large. A 
senior researcher summarized this 
view: 
Accompanied with [a reflec-
tion on how clinical applications 
could be regulated] there [have] 
to be robust public engagement 
exercises, where you really get to 
not only give the information to 
the public but of course also get 
the feedback from the public of 
what they think might be useful, 
might be acceptable, and where 
are the limits. Because of course, 
there [have] to be limits applied to 
the use of this technology. There 
are potential uses which are ben-
eficial, to avoid having serious ge-
netic diseases. But there is a whole 
spectrum going towards more 
trivial applications, or even of en-
hancement, which would be really 
unhelpful and potentially lead to a 
public rejection of the whole no-
tion. (Interviewee 11)
Several participants emphasized 
that, in the United Kingdom, a re-
vision of the law that would enable 
clinical heritable genome editing ap-
plications could take place only if the 
wider public embraced this idea and 
if these applications lay within the 
limits of what society considers ac-
ceptable. In Great Britain, an effort 
to change the law would be initiated 
by the Department of Health. As 
part of this process, the DOH would 
first commission the Human Fer-
tilisation and Embryology Authority 
to conduct public dialogue activi-
ties. The HFEA, in its function as a 
government regulatory body, is sup-
posed to be neutral about any legisla-
tive change, and HFEA staff would 
not lobby government to change the 
law. However, following an order 
from the DOH, the HFEA would 
reach out into the public sphere and 
start a multistakeholder deliberation 
process. Based on the results from 
this process, the DOH would make 
a final decision. This was the pro-
cedure that led, for example, to the 
legislative change that permitted mi-
tochondrial replacement therapy in 
the United Kingdom in 2016.47
However, for heritable genome 
editing, a different procedure might 
be used. The recent report from the 
Nuffield Council on Bioethics rec-
ommended that the coordination of 
societal debate on genome editing 
be done by an independent body or 
commission, and not a government 
body.48 Similar views were expressed 
during the workshop and interviews 
that inform this article. As a senior 
policy advisor pointed out, a robust 
public discussion should go way be-
yond the deliberation activities of 
the HFEA. Consultation of public 
opinions, according to this policy 
specialist, should be instigated by 
various parties, independent social 
scientists, and the HFEA, but also 
from within patient organizations, 
religious groups, and other social and 
civil societal organizations. “There is 
a need,” this individual asserted, 
to have early upstream public en-
gagement that . . . can feed into 
the policy-making process. . . . I 
think it should be [initiated by] 
all sorts of different people. Re-
searchers and [scientific] institu-
tions have to be willing and open 
to talk about what their research-
ers are doing. Funders have to 
be open about it. It [this open-
ness] has to be part of public dis-
courses, you got to allow patient 
groups and consumer groups and 
all other people to have access to 
this information, when they go to 
these [deliberation] fora and talk 
about how they feel about this. 
(Interviewee 9)
Patient groups and other organi-
zations are, of course, likely to use 
results from public deliberation to 
press for a more permissive legisla-
tion, at least if the majority of their 
members want this. The representa-
tives of the two patient organizations 
that took part in our project stated, 
for example, that they would actively 
seek to lobby for regulatory change 
if their communities considered re-
productive gene editing as a desirable 
option. 
International guidelines. Virtu-
ally all interviewees agreed that the 
development of an international 
consensus and international guide-
lines that define how heritable ge-
nome editing should be translated 
into clinical practice was essential. 
While participating stakeholders ac-
knowledged that the development 
of international standards would not 
reach all clinics or researchers in this 
field, certainly not at a global level, 
many project participants supported 
the idea. 
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They saw international guide-
lines for the clinical translation of 
the technology as a way to pro-
mote unified technical and safety 
standards that could facilitate in-
ternational knowledge exchange, 
dialogue, and collaborations, and as 
a basis to identify rogue clinics so as 
to warn patients of irresponsible or 
premature applications. However, 
a challenge for the development of 
international guidelines is that the 
technical procedures and effects of 
clinical heritable genome editing 
interventions are different for each 
disease. As the head of an IVF unit 
stated, the genetic manipulation for 
each genetic condition will be differ-
ent, and there will be different risks. 
There thus needs, as was discussed 
in the workshop, to be a clearly de-
fined strategy and pathway for each 
genetic problem. This need points 
to the potential limits of general 
international guidelines. It indicates 
that, beyond the development of 
a set of broad, overarching criteria 
such as transparent treatment pro-
tocols, reliable preclinical evidence, 
careful peer review, and approval by 
regulatory agencies, more detailed 
criteria and considerations will be 
required for specific genetic condi-
tions so that the health and safety of 
newborns can be ensured.
Another problem participants 
mentioned is that international 
guidelines are not legally enforce-
able and that the implementation 
of these standards is likely to differ 
across the world. A widespread ex-
pectation was that individual clinics 
and researchers would try to cir-
cumvent these international norms, 
possibly at a larger scale. As one par-
ticipant said, 
History has shown that certain 
jurisdictions have been willing to 
tolerate, or perhaps turn a blind 
eye to irresponsible therapeutic 
applications, [more recently] 
particularly in relation to stem 
cell therapies, which have been 
offered without any evidence-
base for their human use. . . . I 
am more skeptical of interna-
tional regulations and treaties 
and their effects, because . . . 
there are those who are willing 
to pursue commercial gain over 
the responsible practice of medi-
cine, and there is a limit to what 
is going to effectively be done on 
a global scale to prevent this hap-
pening. (Interviewee 19)
While most participants ac-
knowledged these challenges, they 
thought nevertheless that interna-
tional guidelines would be an im-
portant and necessary regulatory 
instrument to help prevent misuse 
and to establish a solid evidence 
base. 
Scientific sanctions. Another 
policy option that project partici-
pants generated was scientific self-
governance and the enactment of 
scientific sanction. Although par-
ticipants assumed that irrespon-
sible clinical practices in the United 
Kingdom could be prevented (or, 
if necessary, addressed) by national 
law, the use of scientific sanctions 
was especially seen as a tool to dis-
cipline U.K. clinical researchers or 
corporations that would engage in 
irresponsible research or commer-
cial activities overseas. Participating 
stakeholders were concerned that, 
by operating outside of the United 
Kingdom and in countries with 
permissive, ineffective, or not yet 
fully formed regulatory frameworks 
for heritable genome editing, these 
clinicians, researchers, or companies 
could effectively circumvent U.K. 
law. Most participants saw scien-
tific sanctions as the most effective 
way to prevent problematic clinical 
commercial and research practices. 
A senior IVF clinician summarized 
this position:
I think what worries many of us 
is how this technology could be 
abused and misused and taken 
further than the desire to pre-
vent debilitating diseases, more 
towards the slippery slope to-
ward enhancing the human race 
in ways that are akin [to] the 
eugenics programs that we are 
all too aware of, from the last 
century. That is not a route that 
we want to go down. And there-
fore, I think that this technology 
needs to be very carefully consid-
ered and that we need not only 
to have international consensus 
but the ability to use sanctions 
against those who may misuse 
the technology. (Interviewee 21)
According to most participants, 
strong sanctions were in the interest 
of both patients and the scientific 
community. The following types of 
sanctions were mentioned: exclud-
ing researchers from professional 
societies and international bodies or 
Broad public engagement was seen as a central  
requirement to ensure that regulatory options and 
policies would correspond to the needs and  
perceptions of patients, laypeople, and  
society at large.
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committees, preventing researchers 
from accessing funding, preventing 
publications in top journals, plac-
ing notifications of fraudulent work 
in scientific journals and the media, 
and pressuring overseas clinics that 
collaborate with “irresponsible” U.K. 
researchers and corporations by clari-
fying that they operate outside of in-
ternationally acknowledged norms. 
A limit to these sanctions is that 
they all apply to researchers, yet cli-
nicians and entrepreneurs who are 
not part of the mainstream scientific 
community may not be effectively 
controlled by them. While the nature 
and implementation of these sanc-
tions require further thought, inter-
viewees thought that the enactment 
of sanctions should lie in the hands of 
a variety of stakeholders, such as pro-
fessional organizations, funding bod-
ies, review committees, and journals. 
Public and patient education. A 
fourth policy option addressed the 
question of how patients could be 
prevented from seeking access to risky 
and premature heritable genome ed-
iting applications overseas. Represen-
tatives of patient organizations and 
IVF clinicians concluded that alert-
ing patients to up-to-date facts on the 
stages of clinical development, details 
on possible adverse effects and risks, 
and information about deceptive 
marketing and advertisement strate-
gies would be the most promising 
strategy to influence patient behavior. 
The dissemination of such in-
formation, as several participants 
pointed out, should involve multiple 
stakeholder organizations, such as the 
HFEA, the Medicines and Health-
care Products Regulatory Agency, the 
NHS, and other government bodies, 
scientific associations, and, of course, 
patient organizations. The represen-
tative of a patient organization men-
tioned that “disease societies . . . need 
to put [this information] prominent-
ly on the front page of their websites. 
If you are seeking a treatment for this 
and you contemplate going abroad, 
make sure that what is being offered 
is being done as part of a properly 
conducted trial for the following 
condition. And do not do it other-
wise, because you are most likely not 
benefiting yourself ” (Interviewee 14).
A different mechanism to create 
awareness among patients that par-
ticipants suggested was to publish ex-
amples of irresponsible or fraudulent 
treatments and clinics in the media, 
including social media and websites 
of patient organizations and the 
NHS. As one participant said,
It is going to happen somewhere. 
It might happen because of the 
vanity of scientists or clinicians. It 
might happen because of the van-
ity or ego of prospective parents: 
“I slip you 100,000 dollars to do 
this.” Whether they [clinicians] 
keep it quiet or whether they pub-
lish it depends on how vain or ego 
driven they are. . . . So, make big 
examples of those [cases]. Publicize 
those examples, and hopefully, this 
will deter clinicians, bad clinicians, 
from offering these treatments, 
and hopefully, it will deter mem-
bers of the public [from] seeking 
them out. (Interviewee 9)
Regulation of advertisements. An-
other option that project participants 
identified was to look at, and possibly 
adjust, advertising legislation. To pro-
tect patients from false claims, careful 
consideration of acceptable forms of 
advertising for heritable genome edit-
ing therapies will become important, 
at least once first clinical applications 
become available. This might require 
the adjusting of advertising legisla-
tion so that it is compatible with the 
specific characteristics of heritable ge-
nome editing therapies and to create 
the legal basis for penalties, sanctions, 
or punishments and the introduction 
of a consumer-focused complaints 
system. 
A potential problem, especially 
in the context of transnational re-
productive services, is differences in 
advertising legislation across jurisdic-
tions. Moreover, the expansion of the 
Internet and social media have created 
new possibilities for the marketing of 
reproductive and therapeutic services. 
The ability of online advertising to 
reach worldwide audiences makes the 
enforcement of national laws more 
difficult, if not impossible.49 Due to 
the decentralized and borderless na-
ture of the Internet and to more af-
fordable international travel, national 
governments alone cannot solve the 
problem of irresponsible, transna-
tional advertising practices.50 
A key question discussed in the 
workshop was whether U.K. com-
panies that provide heritable genome 
editing therapies abroad and that use 
false or misleading advertisements to 
attract customers in the global market 
could be prosecuted under the U.K. 
legal framework for advertising. A le-
gal expert in international health law 
explained that this was conditional 
on where the company operates and 
where it is advertising. Much depends 
on the legal situation in the countries 
where the advertising is taking place 
and whether false advertising can be 
prosecuted under domestic law. In 
the United Kingdom, for example, 
the Advertising Standard Authority 
can take steps to enforce the removal 
or amendment of ads that breach the 
rules of Consumer Protection from 
Unfair Trading Regulations, a statu-
tory instrument that was introduced 
in 2008. Failure to abide by the regu-
lations can also result in fines and 
prosecution.51 In other words, at least 
in the United Kingdom, legal action 
has to come from within the country 
where companies operate and adver-
tise their services. 
There was widespread consen-
sus that problematic advertisement 
strategies of U.K. companies abroad 
should be criticized from within the 
United Kingdom. Numerous in-
terviewees thought that the U.K. 
government should take an active 
role in liaising with governments in 
countries where U.K. companies are 
likely to offer controversial heritable 
genome editing therapies. Another 
option discussed by participants was 
that the U.K. government should 
actively discourage companies from 
offering controversial clinical inter-
ventions overseas, for example, by 
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imposing sanctions for U.K. profes-
sionals and companies planning to 
offer nonmedical or “enhancement” 
applications overseas, even if the ap-
plications are made available only to 
participants in research studies.
Toward an Inclusive, Global 
Dialogue
The stakeholder views presented here provide insights into possi-
ble future developments, challenges, 
and risks when human germline gene 
editing is translated from the labora-
tory into clinical practice. Some of the 
stakeholder comments may make as-
sumptions or provide interpretations 
that look unwarranted or unusual 
from other national or regional per-
spectives. However, at present there 
is no comparable work from other 
settings. Further, there is no global 
viewpoint available from which these 
assumptions, expectations, and in-
terpretations could be judged. This 
matter of perspective points up the 
benefits of conducting this kind of 
research. It is exactly these expecta-
tions—well founded or not—that 
will inform policy development in 
the United Kingdom. 
The findings demonstrate the 
complexity of the task to consider the 
prospects, risks, and the regulatory 
requirements and conditions within 
which this technique might be de-
veloped safely. Research participants 
suggested that there is an urgent need 
to engage with these challenges at 
an early stage of public deliberation 
and policy development. They have 
suggested six policy options that, if 
developed further, may have the po-
tential to address and possibly pre-
vent some of the challenges that this 
article identifies. At a more general 
level, it will be crucial to raise aware-
ness of these issues in various contexts 
and to conduct further research to as-
sess the impact of regulatory, social, 
scientific, and cultural variation in 
greater detail, with the aim to inform 
policy-making as the technology de-
velops and a consensus to translate 
it into clinical applications becomes 
more widespread. 
Medium-term, public engagement 
with multiple stakeholders at an in-
ternational level will be important. 
This would allow the comparison of 
expectations and assumptions from 
different countries and would initiate 
a conversation on the development of 
potential future solutions to identi-
fied challenges. 
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